Ph II Early BC Pre-Surgical Biologic Study

ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer

NCT00247481 ·Status: COMPLETED ·Phase: PHASE2

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

NCT00319618 ·Status: COMPLETED ·Phase: PHASE2

Preoperative Cisplatin in Early Stage Breast Cancer

NCT00148694 ·Status: COMPLETED ·Phase: PHASE2

Randomized Phase II Study to Assess PD 0332991 in Breast Cancer

NCT02008734 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX

NCT06723990 ·Status: RECRUITING

PIK3CA in HER2+ BC and pCR Trial

NCT05750693 ·Status: UNKNOWN ·Phase: NA

Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer

NCT00003236 ·Status: COMPLETED ·Phase: PHASE2

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

NCT02390427 ·Status: COMPLETED ·Phase: PHASE1

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

NCT00086957 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

NCT01288092 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer

NCT01959386 ·Status: COMPLETED

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

NCT02955394 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

NCT01928615 ·Status: TERMINATED ·Phase: PHASE2

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

NCT00897026 ·Status: COMPLETED

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

NCT02010021 ·Status: COMPLETED ·Phase: NA

Identification of Early Markers of Response and Resistance to Trastuzumab

NCT01834950 ·Status: COMPLETED ·Phase: NA

The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer

NCT03843346 ·Status: COMPLETED

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

NCT02286362 ·Status: COMPLETED

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

NCT01964391 ·Status: COMPLETED ·Phase: PHASE3

A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

NCT01265927 ·Status: COMPLETED ·Phase: PHASE1

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT05954143 ·Status: TERMINATED ·Phase: PHASE2

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

NCT05338723 ·Status: COMPLETED ·Phase: PHASE3

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

NCT02061423 ·Status: COMPLETED ·Phase: PHASE1

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

NCT04294628 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

NCT04928261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4